Her2-Positive and Microsatellite Instability Status in Gastric Cancer-Clinicopathological Implications.

dc.contributor.authorBermúdez, Ana
dc.contributor.authorArranz-Salas, Isabel
dc.contributor.authorMercado, Silvia
dc.contributor.authorLópez-Villodres, Juan A
dc.contributor.authorGonzález, Virginia
dc.contributor.authorRíus, Francisca
dc.contributor.authorOrtega, María V
dc.contributor.authorAlba, Carmen
dc.contributor.authorHierro, Isabel
dc.contributor.authorBermúdez, Diego
dc.date.accessioned2025-01-07T15:18:37Z
dc.date.available2025-01-07T15:18:37Z
dc.date.issued2021-05-25
dc.description.abstractGastric cancer (GC) is one of the leading causes of cancer-related death. The combination of new molecular classifications with clinicopathological data could contribute to the individualization of patients and to the development of new therapeutic strategies. We examined the various associations in two molecular types of GC: HER2-positive (human epidermal growth factor receptor 2) and microsatellite instability (MSI), assessing their influence on treatment and prognosis. A retrospective study of 142 GC patients was performed with molecular characterization through HER2 overexpression and DNA repair protein expression for MSI. The percentage of HER2-positive tumors was 13.4%, predominantly in men. Correlations were found with intestinal type, metastases, advanced stages and chemotherapy. Almost 75% of HER2-positive patients died. MSI occurred in 16.2%, associated with advanced age, female sex, distal location and intestinal type. These patients had few metastases and low stages. The percentage of deaths was higher among MSI patients who received perioperative chemotherapy. The determination of HER2 and MSI status in GC is important for their association with specific clinicopathological features and for their prognostic and predictive value.
dc.identifier.doi10.3390/diagnostics11060944
dc.identifier.issn2075-4418
dc.identifier.pmcPMC8228707
dc.identifier.pmid34070574
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8228707/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2075-4418/11/6/944/pdf?version=1622000377
dc.identifier.urihttps://hdl.handle.net/10668/27036
dc.issue.number6
dc.journal.titleDiagnostics (Basel, Switzerland)
dc.journal.titleabbreviationDiagnostics (Basel)
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Alto Guadalquivir
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - D.S.A.P. Sevilla Sur
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHER2
dc.subjectclinicopathological features
dc.subjectgastric cancer
dc.subjectmicrosatellite instability
dc.subjectmolecular classification
dc.titleHer2-Positive and Microsatellite Instability Status in Gastric Cancer-Clinicopathological Implications.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8228707.pdf
Size:
10.71 MB
Format:
Adobe Portable Document Format